炎症性关节炎患者心血管风险的管理：实际考量
Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations.
作者信息
Tournadre Anne, Mathieu Sylvain, Soubrier Martin
机构信息
Rheumatology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Rheumatology Department, CHU Gabriel Montpied, 58 Rue Montalembert, F-63000 Clermont-Ferrand, France.
出版信息
Ther Adv Musculoskelet Dis. 2016 Oct;8(5):180-191. doi: 10.1177/1759720X16664306. Epub 2016 Sep 5.
Abstract
Patients with inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, have higher rates of cardiovascular mortality. While the increased cardiovascular risk is only explained to some extent, a lot of research is currently conducted to improve our understanding of its pathogenesis, risk stratification, and optimal cardiovascular risk management. This review sought to report epidemiological data pertaining to the cardiovascular disease burden in patients with inflammatory arthritis, underlying mechanisms accounting for excessive cardiovascular risk, along with recommendations regarding risk assessment and management in this patient population.
摘要
患有炎性关节炎（如类风湿性关节炎、银屑病关节炎或强直性脊柱炎）的患者心血管疾病死亡率较高。虽然心血管风险增加仅在一定程度上得到了解释，但目前正在进行大量研究，以增进我们对其发病机制、风险分层和最佳心血管风险管理的理解。本综述旨在报告与炎性关节炎患者心血管疾病负担相关的流行病学数据、导致心血管风险过高的潜在机制，以及关于该患者群体风险评估和管理的建议。
相似文献
1
Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations.
Ther Adv Musculoskelet Dis. 2016 Oct;8(5):180-191. doi: 10.1177/1759720X16664306. Epub 2016 Sep 5.
2
Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis.
Best Pract Res Clin Rheumatol. 2018 Jun;32(3):369-389. doi: 10.1016/j.berh.2019.01.002. Epub 2019 Mar 6.
3
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3.
4
Cardiovascular disease in inflammatory rheumatic diseases.
Best Pract Res Clin Rheumatol. 2016 Oct;30(5):851-869. doi: 10.1016/j.berh.2016.10.006. Epub 2016 Nov 9.
5
Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
Curr Opin Rheumatol. 2003 Jul;15(4):394-407. doi: 10.1097/00002281-200307000-00005.
6
Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis.
Semin Arthritis Rheum. 2004 Dec;34(3):585-92. doi: 10.1016/j.semarthrit.2004.07.010.
7
Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Cochrane Database Syst Rev. 2011 Oct 5(10):CD008886. doi: 10.1002/14651858.CD008886.pub2.
8
Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic.
Ann Rheum Dis. 2013 Dec;72(12):1968-74. doi: 10.1136/annrheumdis-2012-202789. Epub 2012 Dec 22.
9
Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study.
Arthritis Res Ther. 2017 May 18;19(1):102. doi: 10.1186/s13075-017-1315-z.
10
Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.
BMJ. 2018 Apr 23;361:k1036. doi: 10.1136/bmj.k1036.
引用本文的文献
1
Assessment of Intramuscular Fat and Correlation with Body Composition in Patients with Rheumatoid Arthritis and Spondyloarthritis: A Pilot Study.
Nutrients. 2021 Dec 17;13(12):4533. doi: 10.3390/nu13124533.
2
Real-world implementation of diabetes management by pharmacists: The RING Practice Tool.
Can Pharm J (Ott). 2021 Apr 23;154(3):160-165. doi: 10.1177/17151635211004964. eCollection 2021 May-Jun.
3
Cardiovascular risk estimation in young patients with ankylosing spondylitis: A new model based on a prospective study in Constanta County, Romania.
Exp Ther Med. 2021 May;21(5):529. doi: 10.3892/etm.2021.9961. Epub 2021 Mar 22.
4
RIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre-post intervention study.
BMJ Open. 2021 Mar 24;11(3):e043612. doi: 10.1136/bmjopen-2020-043612.
5
Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis.
ESC Heart Fail. 2020 Dec;7(6):3745-3753. doi: 10.1002/ehf2.12947. Epub 2020 Oct 7.
6
Could Omega 3 Fatty Acids Preserve Muscle Health in Rheumatoid Arthritis?
Nutrients. 2020 Jan 15;12(1):223. doi: 10.3390/nu12010223.
7
Ischemic heart disease and ankylosing spondylitis-assessing the role of inflammation.
Clin Rheumatol. 2018 Apr;37(4):1053-1058. doi: 10.1007/s10067-018-4037-y. Epub 2018 Feb 22.
本文引用的文献
1
Incidence and predictors for cardiovascular events in patients with psoriatic arthritis.
Ann Rheum Dis. 2016 Sep;75(9):1680-6. doi: 10.1136/annrheumdis-2015-207980. Epub 2015 Oct 22.
2
Mortality in ankylosing spondylitis: results from a nationwide population-based study.
Ann Rheum Dis. 2016 Aug;75(8):1466-72. doi: 10.1136/annrheumdis-2015-207688. Epub 2015 Sep 2.
3
Statin use and mortality in rheumatoid arthritis: a general population-based cohort study.
Ann Rheum Dis. 2016 Jul;75(7):1315-20. doi: 10.1136/annrheumdis-2015-207714. Epub 2015 Aug 5.
4
Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study.
Arthritis Rheumatol. 2015 May;67(8):1995-2003. doi: 10.1002/art.39195.
5
Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study.
PLoS One. 2015 May 13;10(5):e0126347. doi: 10.1371/journal.pone.0126347. eCollection 2015.
6
Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis.
Arthritis Rheumatol. 2015 Jul;67(7):1711-7. doi: 10.1002/art.39136.
7
Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study.
Arthritis Rheumatol. 2015 Jul;67(7):1718-28. doi: 10.1002/art.39114.
8
Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
Arthritis Rheumatol. 2015 Jun;67(6):1449-55. doi: 10.1002/art.39098.
9
Paracetamol: not as safe as we thought? A systematic literature review of observational studies.
Ann Rheum Dis. 2016 Mar;75(3):552-9. doi: 10.1136/annrheumdis-2014-206914. Epub 2015 Mar 2.
10
The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis.
PLoS One. 2015 Feb 17;10(2):e0117952. doi: 10.1371/journal.pone.0117952. eCollection 2015.
Zotero 插件